<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="583">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542408</url>
  </required_header>
  <id_info>
    <org_study_id>HERO-19</org_study_id>
    <nct_id>NCT04542408</nct_id>
  </id_info>
  <brief_title>Hamburg Edoxaban for Anticoagulation in COVID-19 Study</brief_title>
  <acronym>HERO-19</acronym>
  <official_title>Hamburg Edoxaban for Anticoagulation in COVID-19 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of
      standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate
      anticoagulation strategy = low-dose low-molecular weight heparin [LMWH], ambulatory no
      anticoagulation, i.e. placebo within this trial) in reduction of morbidity and mortality
      endpoints in patients with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coagulopathy in the context of COVID-19 is a major threat to affected patients due to deep
      vein thromboses and pulmonary embolisms. Actual data show an unexpectedly high incidence of
      partially fatal complications without any prior clinical evidence in some cases. Therefore,
      this prospective, randomized, assessor-blinded, multicenter, placebo-controlled,
      interventional trial will investigate whether therapeutic anticoagulation on top of SOC
      compared to prophylactic anticoagulation as part of SOC- can improve objective
      patient-relative endpoints, relevant for prognosis in patients with COVID-19. 172 eligible
      patients will be randomized 1:1 to experimental or control group. Patients enrolled to
      experimental group will receive therapeutic anticoagulation using LMWH body weight-adapted
      during course of hospital stay and oral anticoagulation using Edoxaban according to SmPC
      (60mg once a day) after being discharged from hospital / outpatient course. Patients enrolled
      to control group will receive prophylactic anticoagulation using LMWH as part of SOC whilst
      inpatient course, and placebo after discharge / outpatient course.

      Patients will be informed of their allocation to the placebo group, as it has been shown that
      the effect of placebo is still detectable (Kleine-Borgmann J, Schmidt K, Hellmann A, et al.:
      Effects of open-label placebo on pain, functional disability, and spine mobility in patients
      with chronic back pain: a randomized controlled trial. Pain 2019; 160 (12): 2891-2897; Blease
      CR, Bernstein MH, Locher C: Open-label placebo clinical trials: is it the rationale, the
      interaction or the pill? BMJ Evid Based Med. 2019).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>All-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism during follow-up (42 days). Thromboembolisms will be detected by duplex ultrasonography of arms and legs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>42 days</time_frame>
    <description>All-cause mortality during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality related to venous thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>Mortality related to venous thromboembolism during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality related to arterial thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>Mortality related to arterial thromboembolism during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of venous and/ or arterial thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>Rate of venous and/ or arterial thromboembolism during follow-up (42 days) Thromboembolisms will be detected by duplex ultrasonography of arms and legs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and length of mechanical ventilation</measure>
    <time_frame>42 days</time_frame>
    <description>Rate and length of mechanical Ventilation during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of initial stay at ICU after application of IMP</measure>
    <time_frame>42 days</time_frame>
    <description>Length of initial stay at ICU after application of IMP during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalisation</measure>
    <time_frame>42 days</time_frame>
    <description>Rehospitalisation during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and length of renal replacement therapy</measure>
    <time_frame>42 days</time_frame>
    <description>Rate and length of renal replacement therapy during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac arrest/ CPR</measure>
    <time_frame>42 days</time_frame>
    <description>Cardiac arrest/ CPR during follow-up (42 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Intensive anticoagulation strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-hospital (ICU &amp; normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate anticoagulation strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In-hospital (ICU &amp; normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation Agents (Edoxaban and/or high dose LMWH)</intervention_name>
    <description>In-hospital (ICU &amp; normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until</description>
    <arm_group_label>Intensive anticoagulation strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Low molecular weight heparin or Placebo</intervention_name>
    <description>In-hospital (ICU &amp; normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban</description>
    <arm_group_label>Moderate anticoagulation strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COVID-19 and hospitalization on ICU, or

          -  Diagnosis of COVID-19 and hospitalization on normal ward, or

          -  Diagnosis of COVID-19 (within 10 days) and troponin ≥ ULN and/or D-dimer ≥0.5 mg/L

        Exclusion Criteria:

          -  Age below 18

          -  Life expectancy less than 3 months before COVID-19

          -  Resuscitation &gt; 30 minutes

          -  Hypersensitivity to the active substance, to Edoxaban or any of its excipients

          -  Significantly increased bleeding risk

          -  Other indication for anticoagulation beyond COVID-19

          -  GFR &lt; 15 ml/min

          -  Planned transfer of the patient to another clinic within the next 42 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Kluge, MD</last_name>
    <phone>+49 40 7410</phone>
    <phone_ext>57010</phone_ext>
    <email>s.kluge@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahir Karakas, MD</last_name>
    <phone>+49 152 22817493</phone>
    <email>m.karakas@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Bode, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans-Jörg Busch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Schäfer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitärsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Kluge, MD</last_name>
      <email>s.kluge@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Welte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Köln-Merheim</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Karagiannidis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TU München Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Lahmer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hartmut Schmidt, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2020</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coagulopathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

